FTC Advertising Substantiation: Competent Scientific Evidence

To make a health claim in advertising, the Federal Trade Commission requires you to hold competent and reliable scientific evidence for that claim before the ad ever runs. In practice, that means randomized, controlled human clinical trials conducted by qualified experts, evaluated against the full body of relevant science. FTC advertising substantiation for health claims is a prior requirement, not a defense you can build after the fact, and civil penalties reach $53,088 per violation, with each day a deceptive ad runs counting as a separate offense.

What Competent and Reliable Scientific Evidence Means

The FTC defines the standard as tests, research, or studies conducted and evaluated objectively by experts in the relevant field, using methods generally accepted in that field to produce accurate and reproducible results. The evidence must be sufficient in both quality and quantity, measured against the entire body of relevant science, to support the specific claim being made.¹

There is no fixed number of studies that automatically satisfies the standard. Replication by independent researchers strengthens the evidence because it reduces the chance that a single trial’s results were skewed by undetected bias. Stacking up numerous flawed studies does not add up to reliable evidence. Quality matters more than quantity.¹

A point that catches many companies off guard: the standard applies uniformly regardless of how the FDA categorizes a product. The FTC draws no bright-line distinction between structure/function claims, health claims, and drug claims. A dietary supplement advertised to “support immune health” faces the same substantiation framework as a product claiming to treat a specific disease. The FDA’s labeling categories under the Dietary Supplement Health and Education Act do not limit the FTC’s authority over advertising.¹

Every Claim Your Ad Communicates Needs Support

Substantiation covers every objective claim the ad makes, whether stated directly or merely implied. An express claim is a direct statement, such as “clinically proven to reduce joint pain.” An implied claim is what a reasonable consumer would take away from the ad’s overall message even if those exact words never appear. A photo of a runner crossing a finish line next to a supplement bottle implies athletic performance benefits, and you need evidence for that implication. If an ad lends itself to more than one reasonable interpretation, you need substantiation for each one.

Establishment claims raise the bar further. Phrases like “tests prove,” “doctors recommend,” or “studies show” tell consumers what kind of evidence sits behind the claim. When you invoke a specific type of evidence, the FTC expects you to actually possess at least that level of support. Saying “clinical studies prove” when you only have animal research is independently deceptive, regardless of whether the underlying product claim happens to be true.²

Why the Evidence You Already Have May Not Qualify

Companies routinely misjudge whether their existing research meets the standard. A few common failure modes:

Animal and In Vitro Studies

Animal research and in vitro studies (experiments on isolated cells or tissue samples) can serve as useful background but do not, on their own, substantiate a claim about what a product does in the human body. Species differences in metabolism, dosing, and biology make animal results hard to extrapolate to people. A reaction in a petri dish does not tell you the same reaction occurs when someone swallows a capsule. When human clinical research is feasible and is what experts in the field consider necessary, animal or lab data alone will not meet the standard.³

Consumer Testimonials

Endorsements and testimonials are not scientific evidence. Federal regulations state directly that advertisers must possess adequate substantiation for claims made through endorsements in the same manner as if they had made the representation themselves. A thousand five-star reviews do not replace a single well-designed clinical trial when the claim involves health.⁴

Researcher Credentials

The “competent” half of the standard is about who designed and evaluated the research. Studies must be conducted by people with genuine expertise in the specific field the claim addresses. A study on cardiovascular benefits should be overseen by a cardiologist or vascular biologist, not a general practitioner with no specialized training in the area. Evidence gets disqualified when the people behind it lack credentials relevant to the health claim. Hiring a credentialed scientist from an unrelated field does not turn their work into authoritative support for a specific therapeutic benefit.¹

Funding and Disclosure

Research funded by the advertiser is not automatically disqualified, but financial connections between scientists and the company create credibility issues that trigger disclosure obligations. Federal regulations require clear and conspicuous disclosure when a material connection exists between an endorser and the seller that consumers would not reasonably expect. For scientific experts, this includes ownership stakes and revenue-sharing arrangements, not just direct payment for appearing in an ad. When you fund outside research and then cite the results in marketing, the fact that you paid for the study should be disclosed. Consumers weigh “independent” research differently from industry-funded work, and hiding the distinction is deceptive.⁵

How the Studies Must Be Designed

For health-related claims, the FTC generally expects randomized, controlled human clinical trials. These protocols isolate the product’s effect from placebo responses, natural improvement over time, and researcher expectations, which is why they are treated as the gold standard.¹

The FTC does not mandate a specific p-value threshold, but results must be statistically significant by the standards generally accepted in the relevant scientific discipline. A study that fails to show a statistically significant difference between the treatment group and the control group may indicate that any observed effect was due to chance or a placebo response.³

Statistical significance alone is not enough. The FTC also looks at whether results translate into a benefit that actually matters to consumers. A supplement might produce a statistically detectable change in a biomarker that is too small to have any real health consequence. That kind of result does not support a claim promising meaningful improvement.³

The agency also watches for data manipulation. When a study measures multiple outcomes, there must be a statistical adjustment to account for the increased probability of a false positive across those measurements. Post hoc analysis that departs from the original study protocol raises red flags. The FTC calls this “p-hacking,” where researchers mine data after the fact to find positive results in a study that otherwise failed to show a treatment effect.³

The Whole Body of Evidence Counts, Not Just Your Best Study

You cannot cherry-pick a favorable study while ignoring a larger body of contradictory research. The FTC evaluates the totality of the scientific evidence, meaning all relevant, well-conducted studies, including those with neutral or negative results. If the prevailing scientific consensus suggests a product is ineffective, one outlier study will not save the claim.¹

When a stronger body of surrounding evidence runs contrary to a claimed effect, even a carefully qualified version of the claim is likely deceptive. This obligation is ongoing. A claim that was well-supported five years ago can become unsupported as the science evolves, and continuing to run the ad after contradictory evidence emerges creates liability.¹

Weight Loss Claims the FTC Treats as Scientifically Impossible

Weight loss advertising draws especially intense scrutiny. The FTC has identified seven categories of claims it considers inherently deceptive for supplements, topical products, and over-the-counter drugs because they are scientifically impossible:

Effortless major weight loss: losing two or more pounds per week for a month or more without diet changes or exercise.
Unlimited eating: losing substantial weight regardless of what or how much someone eats.
Permanent results without continued use: weight stays off after the consumer stops taking the product.
Fat or calorie blocking: the product blocks absorption enough to cause substantial weight loss.
Unsafe rapid loss: safely losing more than three pounds per week for more than four weeks.
Universal effectiveness: the product causes substantial weight loss for all users.
Topical or wearable weight loss: wearing a product or rubbing it on the skin causes substantial weight loss.

“Substantial weight loss” here means more than a pound per week for over four weeks, or more than 15 pounds total. Paraphrasing these claims or adding hedging language does not fix them. The underlying representation remains deceptive regardless of how it is worded.⁶

Disclaimers Cannot Rescue a Claim You Cannot Prove

Fine print does not lower the substantiation burden. A disclosure can limit or clarify a claim to prevent a misleading impression, but it cannot convert a false claim into a lawful one. If the disclosure contradicts the main message of the ad, the claim itself must change or the ad should not run. The FTC has stated that if a platform lacks space for a clear and conspicuous disclosure, and the claim requires one, that platform should not be used for the ad.⁷

Slapping an asterisk on an ad for a supplement claiming to “boost metabolism by 300%” does not fix the problem if you lack clinical evidence for that number. The claim needs to change.

Evidence Must Exist Before the Ad Runs

Timing is one of the most consequential aspects of the doctrine. Evidence has to exist before the claim is published. Running the ad first and commissioning a study later already violates Section 5 of the FTC Act, even if the study eventually confirms the claim. The fact that the product turned out to work does not absolve you of liability for lacking prior substantiation.²

The Commission keeps some discretion over post-claim evidence, but only in narrow situations. It may consider later research when deciding whether to bring a case, when evaluating what the advertiser knew at the time, or when determining the appropriate scope of an order. You are not permitted to create entirely new substantiation after the fact simply because the original support was inadequate.²

What It Costs to Get This Wrong

Civil penalties for violating the FTC Act currently reach up to $53,088 per violation, an amount adjusted annually for inflation. Because each day a deceptive ad continues to run can count as a separate violation, a national campaign can generate enormous exposure in weeks.⁸⁹

Beyond fines, the FTC can seek consumer redress in federal court, including refunds, contract rescission, and compensatory damages. Punitive damages are not available under the statute, but the available remedies often dwarf the civil penalties themselves. In a 2026 case against TruHeight, a company advertising supplements as supporting height growth in children, the FTC obtained an order banning the company from making unsubstantiated health claims and prohibiting reliance on fake reviews written by employees and vendors.¹⁰¹¹

The FTC also uses “Notices of Penalty Offenses,” sent to companies the agency believes may be engaging in practices already found deceptive in prior cases. Receiving one puts a company on formal notice that continued violations carry per-violation civil penalties, effectively removing any argument that the company did not know its conduct was prohibited.¹²

1
Federal Trade Commission. Health Products Compliance Guidance
2
Federal Trade Commission. FTC Policy Statement Regarding Advertising Substantiation
3
Federal Trade Commission. Health Products Compliance Guidance
4
eCFR. 16 CFR Part 255 – Guides Concerning Use of Endorsements and Testimonials in Advertising
5
eCFR. 16 CFR 255.5 – Disclosure of Material Connections
6
Federal Trade Commission. Gut Check: A Reference Guide for Media on Spotting False Weight Loss Claims
7
Federal Trade Commission. Dot Com Disclosures – Information About Online Advertising
8
Office of the Law Revision Counsel. 15 USC 45 – Unfair Methods of Competition Unlawful; Prevention by Commission
9
Federal Register. Adjustments to Civil Penalty Amounts
10
Federal Trade Commission. FTC Takes Action Against TruHeight for Deceptive and Unsubstantiated Advertising
11
Office of the Law Revision Counsel. 15 USC 57b – Civil Actions for Violations of Rules and Cease and Desist Orders
12
Federal Trade Commission. Penalty Offenses Concerning Substantiation